Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCAF1 | Q9Y4B6 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 12/20 | 0.44 |
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21854201 | 1.00 | DCAF1 (0.55) | DCAF1CAPN1GRNSORT1CNR2 | |
| SCHEMBL21854210 | 0.88 | DCAF1 (0.57) | DCAF1CAPN1KDM5BALDH1A1 | |
| SCHEMBL20027866 | 0.88 | DCAF1 (0.57) | DCAF1CAPN1KDM5BALDH1A1 | |
| SCHEMBL23268990 | 0.86 | CAPN1 (0.59) | DCAF1CAPN1 | |
| SCHEMBL20028632 | 0.86 | CAPN1 (0.59) | DCAF1CAPN1 | |
| SCHEMBL21854314 | 0.85 | DCAF1 (0.54) | DCAF1CAPN1GRNSORT1CNR2 | |
| SCHEMBL20027900 | 0.85 | DCAF1 (0.54) | DCAF1CAPN1GRNSORT1CNR2 | |
| SCHEMBL21854144 | 0.84 | DCAF1 (0.53) | DCAF1CAPN1KDM5B | |
| SCHEMBL21854119 | 0.84 | CAPN1 (0.58) | DCAF1CAPN1CNR2ALDH1A1 | |
| SCHEMBL20027905 | 0.84 | CAPN1 (0.58) | DCAF1CAPN1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS INC (US) | 2022-10-13 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| WO-2018064119-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPEUTICS, INC. (US) | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123114-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | DCAF1 3091/4885CAPN1 3/4885GRN 1000/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | DCAF1 3091/4885CAPN1 3/4885GRN 1000/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | DCAF1 3598/4885CAPN1 4/4885GRN 643/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | DCAF1 3091/4885CAPN1 3/4885GRN 1000/4885 |
| US-20220324814-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | DCAF1 3091/4885CAPN1 3/4885GRN 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.